TCGA-D8-A1X8-01A-11R-A14M-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 26
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.410
- UV_RESPONSE_DN+0.400
- ESTROGEN_RESPONSE_EARLY+0.300
- ANDROGEN_RESPONSE+0.270
- ANGIOGENESIS+0.270
- NOTCH_SIGNALING+0.260
- KRAS_SIGNALING_UP+0.240
- TGF_BETA_SIGNALING+0.230
- BILE_ACID_METABOLISM+0.180
- MITOTIC_SPINDLE+0.180
Top 10 suppressed
- MYC_TARGETS_V2-0.540
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
- E2F_TARGETS-0.300
- DNA_REPAIR-0.220
- KRAS_SIGNALING_DN-0.190
- INTERFERON_ALPHA_RESPONSE-0.170
- INTERFERON_GAMMA_RESPONSE-0.170
- MYC_TARGETS_V1-0.170
- G2M_CHECKPOINT-0.160
- GLYCOLYSIS-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A1L6-01A-11R-A13Q-07 | — | A | 0.779 |
| 2 | TCGA-A8-A09A-01A-11R-A00Z-07 | — | B | 0.751 |
| 3 | TCGA-AR-A24M-01A-11R-A169-07 | — | B | 0.734 |
| 4 | f8877925-49e4-420e-8bd8-cac3a47b67d1 | — | — | 0.710 |
| 5 | SRR4296096 | — | cohortA1 | 0.702 |
| 6 | TCGA-CR-7364-01A-11R-2016-07 | — | — | 0.699 |
| 7 | TCGA-BH-A1ET-01A-11R-A137-07 | — | B | 0.689 |
| 8 | ERR2598079 | fetal | fetal | 0.688 |
| 9 | TCGA-A2-A1G0-01A-11R-A13Q-07 | — | A | 0.686 |
| 10 | TCGA-44-6146-01A-11R-1755-07 | — | cohortA1 | 0.681 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.080 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.080 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |